Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir하이드록시클로로퀸, 파비피라비르, 하이드록시클로로퀸과 파비피라비르를 병용한 경증/중등도 COVID-19 환자의 ICU 입원률 비교Observational Study Published on 2021-03-012022-09-11 Journal: Journal of infection and public health [Category] 임상, 치료제, [키워드] adjusted Admission age Analysis applied approach city clinics Combination conducted covariate COVID-19 COVID-19 patient diagnosis of COVID-19 disease effect of treatment effect size eligible Favipiravir group HCQ Hospitalized Hydroxychloroquine ICU ICU admission ICU admission rate indicated intensive care intensive care unit Laboratory median age Mild Mild disease mild to moderate Moderate COVID-19 Multivariate analysis no statistically significant difference observational study Patient patients patients hospitalized Pneumonia Probability Propensity score propensity scores ranged reduced risk retrospective sensitivity analysis significantly higher statistically statistically significant difference study period the patient treated Treatment treatment group variable was used Weighting [DOI] 10.1016/j.jiph.2020.12.017 PMC 바로가기 [Article Type] Observational Study
Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trialRandomized Controlled Trial Published on 2021-03-012022-10-05 Journal: The Lancet. Respiratory Medicine [Category] SARS, 임상, [키워드] 1:1 Admission adverse event Affect age Analysis Angiotensin receptor blockers Angiotensin-converting enzyme assigned Biological Block randomisation blood pressure concealed contraindication country COVID creatinine death diabetes died enrolled evaluate female Follow-up fundraising had no Hierarchical hospital hospitalisation individual inhibitor inhibitors intensive care intention-to-treat population International Invasive mechanical ventilation mean body-mass index mechanical ventilation median Multiorgan dysfunction no difference Older Open-label outcome participant Patient Potassium Primary outcome randomised Randomly receiving recommendations Registered renal renin-angiotensin system required secure serum Seven severity of COVID-19 therapy treatment group Trial two groups web-based randomisation system were excluded with COVID-19 [DOI] 10.1016/S2213-2600(20)30558-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trialSARS-CoV-2 감염과 관련된 급성 호흡 곤란 증후군에 대한 다가 면역글로불린의 조기 치료 효과(ICAR 시험): 무작위 대조 시험을 위한 연구 프로토콜Study Protocol Published on 2021-02-282022-09-01 Journal: Trials [Category] MERS, 임상, 진단, [키워드] 1:1 90% power activities activity acute respiratory distress acute respiratory distress syndrome administration adverse event Alpha ARDS assessment chloride coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 daily living defined died double-blind early treatment Effect effect size Efficacy and safety EudraCT evaluate evaluate the effect failure France functional GRADE grade 3 Hospital stay Hospitalized ICU Immunoglobulin immunomodulatory increase in intensive care intensive care unit Intravenous immunoglobulin IVIG Lung injury mechanical ventilation morbidity mortality rate multicenter Occurrence Organ failure outcome parallel group participant Patient pharmacological treatment placebo group Polyvalent immunoglobulin Primary outcome Randomized Randomized controlled trial receive reduction in respiratory distress SARS-CoV-2 SARS-COV-2 infection Secondary objective Secondary objectives sequential design Sodium chloride SOFA Study protocol subject survival survival rate syndrome the placebo group treatment group Trial Trial registration ventilator-free day Ventilator-free days Volume were infected with COVID-19 [DOI] 10.1186/s13063-021-05118-7 PMC 바로가기 [Article Type] Study Protocol
Impact of low molecular weight heparin administration on the clinical course of the COVID-19 diseaseArticle Published on 2021-02-262022-10-29 Journal: Turkish Journal of Medical Sciences [Category] COVID-19, MERS, [키워드] 95% CI administration Analysis analyzed antiinflammatory biochemical C-reactive protein (CRP characteristic Clinical course clinical impact Clinical symptoms control group coronavirus disease Coronavirus disease-19 COVID-19 COVID-19 disease criterion CRP CRP level D-dimer demonstrated diagnosed with COVID-19 hematologic heparin Impact improvement Laboratory LMWH low molecular weight lymphocyte Lymphocyte count Lymphocytes material medical records Mortality multivariable analysis outcomes participant Patient radiologic Result ROC separated significantly the patient treated Treatment treatment group [DOI] 10.3906/sag-2006-184 PMC 바로가기 [Article Type] Article
An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19Medicine Published on 2021-02-172022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] 1:1 Administered adverse event adverse events age angiotensin receptor blocker angiotensin receptor inhibitors ARBs average Bayesian capillary leakage Comorbidities contributing to control group controls Coronavirus disease 2019 COVID-19 COVID−19 cumulative disease severity Efficacy Endpoint enrolled Enrollment hospital discharge Hospitalized illness IMPROVE incidence incidence rate inclusion criteria Inflammation lAbel losartan Lungs male measure open label oral outcome participant Patient Poisson regression post-hoc randomized trial renin-angiotensin system respiratory respiratory compromise Respiratory failure Safe Safety secondary Sex treating treatment group Trial vital status [DOI] 10.3389/fmed.2021.630209 PMC 바로가기 [Article Type] Medicine
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial경증에서 중등도의 COVID-19 환자의 바이러스 부하에 대한 밤라니비맙 단독 요법 또는 에테세비맙 병용 요법의 효과: 무작위 임상 시험Clinical Trial Published on 2021-02-162022-09-25 Journal: JAMA [Category] MERS, 임상, 진단, 치료법, 치료제, [키워드] 95% CI acute respiratory syndrome age ambulatory patient Analysis antibody bamlanivimab baseline clinical clinical benefit Clinical outcome clinical trial combination therapy combination treatment comparison coronavirus Coronavirus disease 2019 COVID-19 death determine Effect Efficacy End points enrolled etesevimab evaluated evaluation period events Final Hospitalization hypersensitivity reaction Immediate in viral load log measure Mild moderate Moderate COVID-19 monotherapy NCT04427501 neutralizing antibody no significant difference occurred outcome Patient patients with COVID-19 phase 2/3 trial Placebo positive Potential treatment primary end point proportion Randomized receive reduction reported SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 viral load secondary outcome measure secondary outcome measures Spread statistically significant statistically significant reduction Symptoms tested the placebo group Treatment treatment group Viral load women [DOI] 10.1001/jama.2021.0202 PMC 바로가기 [Article Type] Clinical Trial
Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trialCOVID-19 환자에서 고용량 비타민 C의 안전성과 효과: 무작위 공개 임상 시험Randomized Controlled Trial Published on 2021-02-112022-08-13 Journal: European Journal of Medical Research [Category] 임상, 치료제, [키워드] 2019-nCoV added addition age and gender antioxidant body temperature boosting immunity clinical trial conducted control group Controlled trial COVID-19 COVID-19 disease COVID-19 infection discharge effective Effectiveness Efficacy function HDIVC High-dose high-dose intravenous vitamin C High-dose vitamin C Hospitalization Hydroxychloroquine ICU intensive care intensive care unit intravenous IRCT20200411047025N1 Laboratory results Lopinavir Lopinavir/ritonavir median Mortality no significant difference Open-label outcome oxygen oxygen saturation Patient patients peripheral Peripheral capillary oxygen saturations Pneumonia Randomized receiving regimen regimens Result Ritonavir Safety SARS-CoV-2 severe COVID-19 disease Severe COVID-19 Infection significantly significantly lower statistically significant difference treated treatment group treatment regimen Trial registration two group two groups underlying diseases Vitamin Vitamin C water-soluble nutrient [DOI] 10.1186/s40001-021-00490-1 PMC 바로가기 [Article Type] Randomized Controlled Trial
Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial신종 코로나바이러스에 대항하는 직접 항바이러스제: 아지스로마이신(DAWn-AZITHRO), 무작위, 다기관, 공개 라벨, 적응형, SARS-CoV-2에 대해 작용하는 새로운 항바이러스제의 개념 증명 임상 시험 - 아지스로마이신 시험Study Protocol Published on 2021-02-092022-09-10 Journal: Trials [Category] MERS, 임상, 치료제, [키워드] 7-category ordinal scale adaptive Admission amplify antibiotic Antiviral Antiviral effect Azithromycin Belgium blunt Bronchoalveolar lavage Care chance chest CT scan clinical Clinical improvement clinical trial coronavirus SARS-CoV-2 Course COVID COVID-19 COVID-19 disease cytokine cytokine signaling decrease defined diagnosed with COVID-19 Diagnosis Direct discharge disease disease course drug Efficacy eligible EudraCT feature health regulations Hospitalized hospitalized patient hospitalized patients Hydroxychloroquine hyperinflammatory state immunomodulatory properties implicated in vitro include Inclusion Intervention life Local Macrolide medical need multicenter name Nasopharyngeal swab National Novel coronavirus novel coronavirus SARS-CoV-2 Open-label Ordinal Scale pathway Pathways Patient patients patients with COVID-19 PCR Phase 2 Primary outcome proof-of-concept clinical trial radiological Randomized Randomized controlled trial receive recruit SARS-CoV-2 severe COVID-19 disease shown Standard Standard of care study inclusion supplementary material Support sustained symptomatic the disease the WHO treatment effect treatment effects treatment group treatment strategy Trial Viral viral replication widespread with COVID-19 [DOI] 10.1186/s13063-021-05033-x PMC 바로가기 [Article Type] Study Protocol
A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 InfectionsResearch Article Published on 2021-02-092022-10-27 Journal: Biochemistry Research International [Category] COVID-19, [키워드] Administered administration ALT AST clinical clinical study clinical symptom Combination conducted Control COVID-19 COVID-19 vaccine creatinine CRP decrease demographic data diagnosed dose double-blind doxycycline drug drug combination effective Efficacy and safety elevated evaluate group Hydroxychloroquine IL-10 IL-6 IL-6 levels increase in Indonesia Infection infections material measure Mild Mild symptom moderate Moderate COVID-19 multicenter observation older patient Other overcome participated Patient PCR PCR swab produced Randomized reduced required Result RT-PCR test Safety Serum level setting significant decrease significantly significantly lower subject TNF- α treat treated Treatment treatment for COVID-19 treatment group virus load [DOI] 10.1155/2021/6685921 PMC 바로가기 [Article Type] Research Article
Homeopathy for Covid-19 in Primary Care: A structured summary of a study protocol for a randomized controlled trial일차 진료에서 Covid-19에 대한 동종 요법: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-02-012022-08-31 Journal: Trials [Category] MERS, 임상, 치료제, [키워드] 1:1 6 hour 6 hours acute respiratory syndrome Adverse adverse events alcohol alternative hypothesis appearance blinded Blinding block randomization bottle Brazil changed changes chest pain clinical trial cough COVID-19 defined dissemination dose double-blind Effectiveness elapsed element emergency services Fever followed by headache Home isolation homeopathic medicine homeopathic medicines Homeopathy hospitalizations identity Influenza Influenza-like symptoms Informed consent investigators measure medication Medicine Medicines Mild mild case mild cases muscle aches network null hypothesis number objective Older outcome Pain participant performed Placebo placebo-controlled positive RT-PCR primary care primary endpoint Primary Health Care protocol randomisation randomised Randomized Randomized controlled trial Randomized Controlled Trial protocol recorded Recovery time recruitment Registered required respiratory Sample size SARS-CoV-2 secondary Severe acute respiratory syndrome shakes sore throat statistician status study medication Study protocol submitted supplementary material Symptom Telemedicine Time to recovery tiredness treatment group Trial two group two groups Unified Health System university website without symptoms [DOI] 10.1186/s13063-021-05071-5 PMC 바로가기 [Article Type] Letter